Navigation Links
NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
Date:4/16/2008

an oral formulation from the series for neural tumors, such as those found in Neurofibromatosis Type 2, and for neurodegenerative disorders."

Tyler E. Jacks, PhD, director of the David H. Koch Institute for Integrative Cancer Research at MIT and Chairman of the Scientific Advisory Board of NexGenix, was named President-Elect of the AACR at the meeting yesterday. Dr. Jacks has previously served in several leadership positions for the AACR, including the Board of Directors and the Nominating Committee. He serves on the editorial board of Molecular Cancer Therapeutics and was a senior editor of Molecular Cancer Research. He is a previous recipient of the AACR Award for Outstanding Achievement in Cancer Research.

About NexGenix Pharmaceuticals

NexGenix Pharmaceuticals is a US-based biotechnology company developing a novel Hsp90 inhibitor series for cancer, neural tumors and neurodegenerative disorders. NexGenix has assembled a team of top scientific advisors in cancer research, Hsp90 inhibitors and medicinal chemistry. The company's lead Hsp90 compound, NXD30001, is in preclinical development for breast cancer.

For more information, please visit the NexGenix website at http://www.nexgenixpharm.com. The information on our website does not, however, form a part of this press release.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Certain information contained in this news release is forward-looking and is subject to unknown risks and uncertainties. The actual results, performance or achievements of the company may differ materially from the results, performance or achievements of the company exp
'/>"/>

SOURCE NexGenix Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ) ... separate underwritten offerings of 10,000,000 shares of its Common ... per share, for expected gross proceeds of $20 million ... Stock at a price to the public of $2,000.00 ... Each share of Series A Convertible Preferred Stock is ...
(Date:9/18/2014)... diseases that afflict skeletal growth through abnormalities in ... fetal stage and is caused by genetic mutations. ... factor receptor 3 (FGFR3) has been associated with ... a skeletal dysplasia that cause serious respiratory problems ... (ACH), which causes stunted growth and other complications ...
(Date:9/18/2014)... memory device for computing may have just taken an ... New York led by chemist Stephen O,Brien have discovered ... properties. , Combining both properties is very exciting scientifically ... for the devices that might ultimately be designed, in ... a single material, however, has proved difficult until now. ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Oxides discovered by CCNY team could advance memory devices 2
... , , , , , , ... 11/1999 , , , , , , , ... Cell line , COS-1, monkey, kidney, , ... pEGFP-N1 (in bidistilled H 2 O), , , ...
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.510 12/2001 , ... , , , , , ... , Cell type , Bacteria, ...
... , , , , , , ... 915.032 03/2000 , , , , , , ... Cell line , BW 5147, mouse lymphoma T-cell line, ... Plasmid pEGFP-N1 (in bidistilled H 2 O), , ...
Cached Biology Technology:COS-1 2Corynebacterium glutamicum 2BW 5147 2
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... manipulate spoken language is unique to humans. "The genetic ... of human evolution to make this possible are largely ... now have," says Wolfgang Enard, Professor of Anthropology and ... the molecular biological basis of language Enard has now ... latest study, undertaken in collaboration with scientists at several ...
(Date:9/18/2014)... seem to be cheerful, happy-go-lucky characters, so you might ... life. , In fact some dogs are distinctly ... Sydney shows. , "This research is exciting because ... objectively and non-invasively. It offers researchers and dog owners ... that changes," said Dr Melissa Starling, from the Faculty ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... California, Davis, have invented a superthin "nanoglue" that could ... itself (say, semiconductor wafers) would break before the glue ... He and his fellow researchers have filed a provisional ... two surfaces. Pan,s nanoglue, which conducts heat and can ...
... As scientists continue the hunt for energy sources that ... amount of valuable farmland is being used to produce ... sources are renewable, economists and ecologists fear that diverting ... drive up costs. Now, Prof. Avigdor Abelson ...
... addressing the major challenges facing humanity in the 21st Century, ... Perspective published in The Plant Cell , the two ... to transforming plant biology in order to meet human needs. ... the biosphere, provide food and materials used by humans, and ...
Cached Biology News:Is seaweed the future of biofuel? 2The future of plant science a technology perspective 2
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
NEWBORN CALF SERUM AND PLASMA...
Synaptic Vesicle I Sampler Kit 10g each...
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Biology Products: